A Novel Intergenic Region (chr2: 30,316,870)- ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report

Anaplastic lymphoma kinase ( ) rearrangements have been reported as an important oncogenic driver in 5-7% non-small cell lung cancer (NSCLC) patients. Reports about the intergenic region (IGR) as an fusion partner are rare. In this study, we report a novel IGR (chr2: 30,316,870)- fusion in an advanc...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2024-01, Vol.17, p.261-265
Main Authors: Zhou, Danfei, Ying, Jun, Hu, Shanshan, Li, Jiangdong, Liu, Haijian
Format: Article
Language:English
Subjects:
Adenocarcinoma
Antimitotic agents
Antineoplastic agents
Cancer
Cancer patients
Care and treatment
Case Report
Chemotherapy
Genetic aspects
Health aspects
Lung cancer, Non-small cell
Lung diseases
Lymphomas
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anaplastic lymphoma kinase ( ) rearrangements have been reported as an important oncogenic driver in 5-7% non-small cell lung cancer (NSCLC) patients. Reports about the intergenic region (IGR) as an fusion partner are rare. In this study, we report a novel IGR (chr2: 30,316,870)- fusion in an advanced lung adenocarcinoma patient that responded effectively to crizotinib combined with pemetrexed. A 68-year-old Chinese female was diagnosed with stage IV right lung adenocarcinoma (cT3N3M1c). The targeted next-generation sequencing (NGS) of 14 cancer-related genes identified an IGR (chr2: 30,316,870)- fusion. Her lung lesions have been successfully converted from a partial response to a complete response after administrating crizotinib for 1 year combined with 6 cycles of chemotherapy with pemetrexed. So far, her progression-free-survival has reached 21 months. In this case, we firstly report a novel IGR (chr2: 30,316,870)- fusion by using targeted NGS, and highlight the efficacy of crizotinib combined with pemetrexed to reduce unbearable gastrointestinal adverse reactions. It provides valuable clinical guidance for the treatment of similar cases in the future.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S444624